Progress in tumor-targeted superantigen research

Immunotherapy is a hotspot and future trend in the field of tumor research.in the process of tumor immunotherapy, the targeting specificity of drugs to tumor tissues and the effectiveness of drugs in activating immune system in tumor microenvironment are the key to successful treatment.superantigen molecules can effectively activate the immune response of human body at very low doses, and produce effective immune killing to tumor cells and solid tumors. It is a promising tumor immunotherapeutic agent.relying on the Key Laboratory of super antigen research in Shenyang, the research group of microbial resources and ecology of Shenyang Institute of Applied Ecology, Chinese Academy of Sciences, is committed to the study of structure-activity relationship, structural transformation and development of immune and anti-tumor drugs.recently, Xu Mingkai, a researcher at Shenyang Institute of ecology, innovatively fused irgd, a tumor targeting transmembrane penetrating peptide, and st-4, an enhanced superantigen modifier, to construct a new tumor targeting superantigen st-4-irgd.in this study, 4T1 breast cancer cell line and B16F10 melanoma cell line were selected to systematically evaluate the tumor targeting and antitumor activity of st-4-irgd in vitro cell model and tumor bearing mouse in vivo model.studies have found that st-4-irgd can specifically target and penetrate into tumor tissue, and show significantly enhanced tumor inhibition rate. Solid tumor is significantly reduced and survival time is significantly prolonged.the study also found that the introduction of targeted molecules significantly enhanced the tissue distribution of superantigens in tumor microenvironment, effectively enhanced the infiltration of lymphocytes in solid tumor tissues, and played a stronger role in tumor immunotherapy.in addition, no toxic effects induced by st-4-irgd were found in the whole research process, so it has the prospect of new drug development.with the title of anirgd peptide fused supernumerator induced tumor targeting and t Lymphacyte infiltracting in cancer immunotherapy, the research was published in the International Journal of pharmaceuticals in 2020.doctoral student song Yubo is the first author of the paper, and Xu Mingkai is the corresponding author.the research has been supported by the strategic leading science and technology project of Chinese Academy of Sciences (a), Liaoning Xingliao Talents Program, and young and middle-aged scientific and Technological Innovation Talents Program of Shenyang Science and Technology Bureau.figure. Schematic diagram of action mechanism of tumor targeting super antigen st-4-irgd and its targeted anti-tumor effect source: Shenyang Institute of Applied Ecology, Chinese Academy of Sciences